Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
Andrea F. Wainer, the retired Executive Vice President of Abbott Laboratories (NYSE:ABT), recently sold shares of the company’s stock. According to a Form 4 filing with the Securities and Exchange Commission, Wainer sold 949 shares on March 3, 2025, at a price of $138.17 per share, totaling $131,123. This transaction reduced her direct ownership to 74,381 shares. The timing of the sale comes as Abbott trades near its 52-week high of $141.23, with the stock showing strong momentum over the past three months. InvestingPro analysis indicates the stock is currently trading above its Fair Value, with technical indicators suggesting overbought conditions.
Additionally, Wainer disposed of 7,313 shares on February 28, 2025, at a price of $135.87 per share, in a transaction valued at $993,617. These transactions reflect Wainer’s continued management of her holdings in the pharmaceutical giant. With a market capitalization of $243.19 billion and an overall financial health score rated as "GREAT" by InvestingPro, Abbott maintains its position as a prominent healthcare equipment & supplies industry leader. Investors can access 15+ additional exclusive ProTips and comprehensive analysis through Abbott’s detailed Pro Research Report.
In other recent news, Cadrenal Therapeutics has announced a collaboration with Abbott to conduct a pivotal clinical trial for their drug tecarfarin, aimed at improving treatment for patients with left ventricular assist devices. The partnership will leverage Abbott’s expertise in the field to enhance trial design and patient enrollment. This collaboration is part of Cadrenal’s strategy to address unmet needs in cardiovascular care. Meanwhile, Abbott Laboratories has seen several analyst firms adjust their price targets and ratings. Barclays (LON:BARC) raised its price target for Abbott to $158, maintaining an Overweight rating, citing management’s updated financial outlook and increased gross margin expectations despite foreign exchange and tax rate challenges. Bernstein also increased Abbott’s price target to $138, maintaining an Outperform rating, highlighting strong performance in the Medical (TASE:BLWV) Devices segment with notable growth in Continuous Glucose Monitoring and Structural Heart products. Additionally, UBS raised its price target for Abbott to $148, reiterating a Buy rating, based on Abbott’s financial guidance for fiscal year 2025 and expectations of continued growth in its MedTech portfolio. These developments reflect a positive outlook on Abbott’s financial performance and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.